Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical data trend for Metacare Co's OCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XKRX:118000 vs LLY, JNJ, ABBV: OCF Margin % Comparison
For the Drug Manufacturers - General subindustry, Metacare Co's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Metacare Co OCF Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Metacare Co's OCF Margin % distribution charts can be found below:
* The bar in red indicates where Metacare Co's OCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Metacare Co (XKRX:118000) has a OCF Margin % of 11.19% as of Jun. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Metacare Co and its competitors. According to the industry distribution chart, Metacare Co ranks #505 out of 965 companies in the Drug Manufacturers industry, placing it in the top 52.3%.
Is Metacare Co's OCF Margin % too high?
Metacare Co's current OCF Margin % is 11.19%. The Drug Manufacturers industry median OCF Margin % is 10.04. Metacare Co's value of 11.19% is 11.5% above this industry median. Based on the distribution chart, Metacare Co ranks #505 out of 965 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Metacare Co has a GF Score™ of 42/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Metacare Co's OCF Margin % compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Metacare Co ranks #505 out of 965 companies for OCF Margin %. This places Metacare Co in the lower half of its industry. The industry median OCF Margin % is 10.04. Metacare Co's value of 11.19% is 11.5% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Drug Manufacturers company?
The median OCF Margin % among Drug Manufacturers companies is 10.04, based on 965 companies in the industry. Companies in the top quartile (top 25%) have a OCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Metacare Co's current OCF Margin % of 11.19% is 11.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Metacare Co and its competitors. For the Drug Manufacturers industry, the median OCF Margin % is 10.04 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Metacare Co's current OCF Margin % is 11.19%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Metacare Co stock overvalued right now?
Based on GuruFocus' analysis, Metacare Co (XKRX:118000) is currently considered Possible Value Trap. The stock's GF Value™ is ₩5,177.27, compared to a current price of ₩1,328.00 — trading 74.3% below its estimated fair value. The current OCF Margin % is 11.19% and 11.5% above the Drug Manufacturers industry median of 10.04. Metacare Co's overall GF Score™ is 42/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Metacare Co (XKRX:118000), the current OCF Margin % is 11.19% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Metacare Co (XKRX:118000) Overvalued in 2026?
Based on GuruFocus' analysis, Metacare Co stock appears to be undervalued.
The current stock price of ₩1,328.00 is trading 74.3% below its estimated GF Value™ of ₩5,177.27.
GuruFocus considers Metacare Co to be Possible Value Trap.
Key valuation signals for XKRX:118000:
OCF Margin %: 11.19%
GF Value™: ₩5,177.27 vs. price of ₩1,328.00 (74.3% below fair value)
Industry Position: 11.5% above the Drug Manufacturers median (#505 of 965)
No single metric tells the full story. See the XKRX:118000 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Metacare Co Ltd formerly Smedi Co Ltd has established a hospital in Jeju and exports various types of medical equipments. The company also built its own hospital in China and India and plans to expand its business in Spain and Dubai. The Company and its subsidiaries are divided into pharmaceutical business, medical business, wireless device business, investment and others according to business characteristics by business sector.
42GF Score
Get the complete analysis for XKRX:118000
OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XKRX:118000 has been successfully added to your 
